Menu
Minicircle is running a Phase I clinical trial on an HIV gene therapy with the potential to cure HIV. The therapy is designed for distribution in high-temperature climates resulting in scalable eradication of the virus.
Minicircle is also running a Phase I clinical trial on a follistatin gene therapy that may be able to treat or delay the onset of ALS and facioscapulohumeral muscular dystrophy.
APPLY TO JOIN A TRIAL
Currently in: Phase I
Trial recruitment active now
Our innovative HIV plasmid therapy constantly delivers human origin broadly neutralizing antibodies discovered by the US National Institutes of Health. This therapy is designed to be distributed in high temperature climates like Africa, India, and Central America and does not require refrigeration. Our hope is that this therapy can be proven both as a “functional cure” for HIV as well as a safe and effective prophylactic designed for global eradication of HIV.
Currently in: Phase I/II
Trial recruitment begins 2022
We believe follistatin gene therapy could be beneficial for treating FSHD for these simple reasons:
1. Follistatin gene therapy has been shown in FDA Phase II clinical trial results to be safe and effective at improving muscle size and walking distance over 180 days in patients with more severe forms of muscular dystrophy than FSHD.
2. Follistatin decreases chronic inflammation in all body tissues (Collins, 2017), improves neuromuscular junction innervation and function (Iyer, 2021), and improves muscle size, endurance, and power in rodent models of ALS (Holzbaur, 2006) as well as in humans. Follistatin gene therapy improves outcomes in mice with a form of Duchenne’s muscular dystrophy.
3. FSHD patients exhibit higher levels of myostatin inhibition than most other muscle wasting diseases, so follistatin is likely to be more effective against it. (Giesige, C et al., 2018).
Currently in: Phase I/II
Trial recruitment begins 2023
Dyskeratosis congenita is a genetic disease which causes children’s telomeres to degrade extremely quickly. We can deliver hTERT via a plasmid gene therapy with the intentions of minimizing the symptoms of, and possibly curing the disease.
Currently in: Phase I/II
Recruitment 2023
A combination of antibodies and morphogenetic proteins can be delivered to create an expected 25% decrease in body fat with a single injection.
Currently in: Phase I/II
Trial recruitment begins 2022
We believe follistatin gene therapy could be beneficial for treating ALS for these simple reasons:
1. Follistatin gene therapy has been shown in FDA Phase II clinical trial results to be safe and effective at improving muscle size and walking distance over 180 days in muscular dystrophy patients.
2. Follistatin decreases chronic inflammation in all body tissues (Collins, 2017), improves neuromuscular junction innervation and function (Iyer, 2021), and improves muscle size, endurance, and power in rodent models of ALS (Holzbaur, 2006) as well as in humans. These three attributes address the unique manifold pathology of ALS.
3. Low follistatin levels are a key biomarker of ALS — only three proteins are reduced in ALS patients’ cerebral spinal fluid: follistatin-315, interleukin-1 alpha, and kallikrein-5. (Lind, A L et al, 2016).
Currently in: Phase I/II
Recruitment begins 2022
Testosterone is a master regulator hormone controlling self-confidence, risk-taking behavior, emotional stability, body composition, rational thinking, cognitive well-being, and libido. Low testosterone levels are endemic in modern civilization where sedentary lifestyles are common and industrial hyperestrogenic compounds are constantly consumed in our air, water, and food. To be considered for entrance into this trial you must have a testosterone level of lower than 700 ng/dL.
Currently in: Phase I/II
Recruitment begins 2023
Our herpes gene therapy works similarly to our HIV gene therapy. Broadly neutralizing antibodies that bind to HSV 1 & 2 can be constantly produced and secreted into the bloodstream in hopes of eliminating the transmission and symptoms of HSV.
Currently in: Phase I/II
Recruitment begins 2023
Our innovative therapy for Crohn’s disease uses plasmids to deliver TNF-alpha neutralizing antibodies at a constant rate for 1-2 years. This therapy, if successful should be able to replace the functionality of existing biologics.